DUAVIVE

This brand name is authorized in Austria, Brazil, Canada, Croatia, Estonia, Finland, France, Ireland, Israel, Lithuania, Mexico, Netherlands, New Zealand, Poland, Spain, Turkey.

Active ingredients

The drug DUAVIVE contains a combination of these active pharmaceutical ingredients (APIs):

1	Bazedoxifene UNII J70472UD3D - BAZEDOXIFENE ACETATE
	Read more about Bazedoxifene
2	Estrogens, conjugated UNII IU5QR144QX - ESTROGENS, CONJUGATED
	The active ingredients of conjugated estrogens are primarily the sulfate esters of estrone, equilin sulfates, 17α-estradiol and 17β-estradiol. These substitute for the loss of estrogen production in menopausal women, and alleviate menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy.
	Read more about Estrogens, conjugated

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03CC07	Conjugated estrogens and bazedoxifene	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03C Estrogens → G03CC Estrogens, combinations with other drugs
Discover more medicines within G03CC07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	522718110082501
CA	Health Products and Food Branch	02432854
EE	Ravimiamet	1674008
ES	Centro de información online de medicamentos de la AEMPS	114960001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	492196
FR	Base de données publique des médicaments	60120666
IL	מִשְׂרַד הַבְּרִיאוּת	7999
LT	Valstybinė vaistų kontrolės tarnyba	1075286
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	158M2017
NL	Z-Index G-Standaard, PRK	125989
NZ	Medicines and Medical Devices Safety Authority	17788
PL	Rejestru Produktów Leczniczych	100334755
TR	İlaç ve Tıbbi Cihaz Kurumu	8699532039095, 8699532039156